NYSE:LLYPharmaceuticals
How Illumina’s Billion Cell Atlas Expansion Could Reshape Eli Lilly’s (LLY) Drug Discovery Edge
In July 2026, Illumina announced that its Billion Cell Atlas alliance, originally launched with AstraZeneca, Merck, and Eli Lilly, had expanded to include three additional AI‑focused drug developers and surpassed 350 million sequenced cells across more than 200 disease‑relevant cell lines.
This rapidly growing CRISPR-based dataset, targeting one billion cells and generating several petabytes of genomic data, could materially enhance Eli Lilly’s ability to uncover new drug targets and...